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Abstract
Background:   The present study was designed to analyze the chronic renal response to
omapatrilat, a new vasopeptidase inhibitor, in spontaneously hypertensive rats (SHR). To that end,
the renal and blood pressure response to a 4-day salt loading protocol was analyzed and the
respective chronic renal curves constructed.
Results:  In non treated animals, and under normal sodium intake (around 2 mEq/day), mean
arterial pressure (MAP), was significantly higher in the SHR as compared with the controls (WKY).
After increasing salt intake (8 times normal), MAP did not change significantly in any group and the
animals reached a normal sodium balance in four days. In a second group of animals, omapatrilat
was given orally for 15 days at the dose of 40 mg/kg/day in the drinking water. In these omapatrilat-
treated animals, and under normal sodium intake, MAP was significantly lower in both groups,
although the antihypertensive effect was much greater in the SHR, so that the MAP of the SHR
group was completely normalized and similar to the WKY-treated group. The subsequent elevation
of sodium intake did not significantly elevate MAP in any group and the animals could manage the
sodium excess as well as the non treated groups.
Conclusions:  These results indicate that chronic treatment with omapatrilat normalizes blood
pressure in SHR without affecting adversely the renal ability to eliminate a sodium load. Chronic
treatment with omapatrilat resets the chronic pressure natriuresis relationship of the SHR to a
normal level, thus without altering the normal salt-independence of this arterial hypertension
model.
Background
Vasopeptidase inhibitors, agents that inhibit both neu-
tral endopeptidase and angiotensin-converting enzyme,
have recently emerged as a novel pharmacological tool
for the treatment of cardiovascular and renal diseases.
Omapatrilat, one of this new inhibitors, has been shown
to be very effective as an antihypertensive agent. In fact,
different laboratories have shown that the omapatrilat
antihypertensive effects are greater than those obtained
with other commonly used antihypertensive drugs, such
as angiotensin converting enzyme inhibitors (ACEI) [1].
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It is known that the mechanism of action of omapatrilat
is double. On one hand, it reduces the formation of angi-
otensin II. On the other hand, it allows the accumulation
of natriuretic factors, such as bradykinin. Thus, omapat-
rilat affects both the vascular tone and renal function,
and this has been documented in several forms of exper-
imental hypertension [2–4]. However, the characteriza-
tion of an antihypertensive drug such as omapatrilat can
not be considered complete unless the pressure natriure-
sis relationship is determined. It is known that a reset-
ting of the pressure natriuresis mechanism is involved in
the antihypertensive effect of many drugs [5]. Thus, an-
giotensin converting enzyme inhibitors reduce blood
pressure but also the slope of the pressure natriuresis re-
lationship, thus making blood pressure sensitive to salt
intake [6,7]. The presence of an additional direct natriu-
retic effect in the omapatrilat molecule may change the
pressure natriuresis relationship in a different way as as
with ACEIs. Thus, in the present study we have examined
the chronic pressure natriuresis relationship during the
administration of omapatrilat in the SHR model of ex-
perimental hypertension.
Results
In the non treated animals and under normal sodium in-
take, mean arterial pressure (MAP, figure 1), was signifi-
cantly higher in the SHR (165. 1 ± 1.8 mmHg) as
compared with the controls (WKY, 124.5 ± 2.8). After in-
creasing salt intake (8 times normal), MAP did not
change significantly in any group (161.8 ± 2.0 and 124.9
± 3.6, respectively). There were no significant differences
in sodium balance while the animals were on a normal
sodium intake. After elevating sodium intake, these ani-
mals reached a normal sodium balance in four days (fig-
ure 2).
In a second group of animals, omapatrilat was given
orally for 15 days at the dose of 40 mg/kg/day in the
drinking water. In these omapatrilat-treated animals,
and under normal sodium intake, MAP was significantly
lower in both groups (112.4 ± 2.7 and 112.7 ± 2.7, in SHR
and WKY respectively), although the antihypertensive
effect was much greater in the SHR, so that the MAP of
the SHR group was completely normalized and similar to
the WKY-treated group. The subsequent elevation of so-
dium intake did not significantly elevate MAP in any
group (118.1 ± 1.7 vs 113.9 ± 2.7, respectively, figure 1).
These omapatrilat-treated animals could also manage
the sodium excess as well as the non treated groups (fig-
ure 2).
There were no important changes in renal glomerular fil-
tration rate (GFR). Under normal sodium intake, the
GFR of the WKY group was 1.7 ± 0.1 ml/min/gkw and 1.6
± 0.1 in the SHR. The elevation of sodium did not change
significantly GFR in any group. Pretreatment with oma-
patrilat did not produce statistical differences between
groups (1.5 ± 0.1 in WKY and 1.7 ± 0.1 in the SHR) under
the normal sodium intake and the increase of sodium in-
take also was without an effect.
Discussion
In the present study we have characterized the antihy-
pertensive effect of omapatrilat in the spontaneous arte-
rial hypertensive rat model by analyzing the renal and
blood response response to an elevation of salt intake.
The characterization of the chronic pressure natriuresis
relationship allows a precise estimation of the kidney-
fluid mechanism that controls arterial pressure, as stated
by Guyton and coworkers in a very elegant series of ex-
periments [8]. As opposed to the acute pressure natriu-
resis relationship, which has to be performed in
anesthetized animals by changing the renal perfusion
pressure [9,10], the chronic pressure natriuresis rela-
tionship characterized in the present report is obtained
in undisturbed animals by changing the intake of salt
and water. In any case, however, both approaches should
give the same estimate of the so-called equilibrium point
at which blood pressure is set for any intake of sodium
and water. This equilibrium point, also called set-point,
is therefore the blood pressure that will be reached in the
long-term, in any physiological or pathological situation
[5,6].
Figure 1
Chronic renal function curves in SHR and WKY rats before
and during chronic treatment with omapatrilat. MAP, mean
arterial pressure.BMC Pharmacology 2001, 1:5 http://www.biomedcentral.com/1471-2210/1/5
The results contained in this manuscript clearly show, as
in other previous studies, that omapatrilat is a very po-
tent antihypertensive effect. In fact, it has been reported
that omapatrilat appears to have even greater antihyper-
tensive effects in SHR than ACEIs alone [1]. In our
hands, blood pressure was normalized by the chronic
treatment with omapatrilat, while in other studies using
only an ACEI such as enapatrilat, blood pressure re-
mained slightly above the normal values [11]. The mech-
anisms behind this beneficial effect of omapatrilat may
be double. Both the decrease in the formation of angi-
otensin II and the accumulation of natriuretic peptides
should, at least theoretically, contribute to the decrease
in blood pressure, through both a vasodilatory action
and the elimination of more salt and water.
Figure 2
Daily sodium balance in SHR and WKY rats before and during chronic treatment with omapatrilat. *, p < 0.05 vs groups.BMC Pharmacology 2001, 1:5 http://www.biomedcentral.com/1471-2210/1/5
Although the blood pressure lowering effect of va-
sopeptidase inhibitors has been shown by many different
laboratories, its effects on renal function have not been
characterized. Our results clearly demonstrate that oma-
patrilat does not negatively affect the renal function of
the hypertensive animals. Thus, glomerular filtration
rate was not adversely affected and also the ability to
eliminate a salt excess was also very well preserved, in a
similar way as the untreated normotensive rats. Thus,
the slope of the chronic pressure natriuresis curve was
not depressed, neither by the decrease in blood pressure
nor by the drug itself, and the steepness of this relation-
ship was maintained at the same level as the controls.
Previous studies using converting enzyme inhibitors in
normal animals have shown that they effectively de-
crease blood pressure, even to hypotensive levels, but the
slope of the chronic pressure natriuresis relationship is
somewhat depressed, thus making blood pressure salt-
sensitive [5–8]. In the present experiments, however,
the chronic pressure natriuresis curve of the normoten-
sive animals treated with omapatrilat was displaced to
the left, that is to lower pressures, but the slope was not
significantly changed, remaining essentially the same.
Thus, the normotensive animals were not salt-sensitive
before the administration of the drug and they also re-
mained salt-resistant after being treated with the va-
sopeptidase inhibitor. The same can be safely said for the
hypertensive animals. It is likely that the difference be-
tween ACEIs alone and omapatrilat may be related to the
greater natriuretic potency of the latter. In fact, the oma-
patrilat-treated SHR showed a greater ability to excrete
the sodium load, as evidenced by the lower sodium re-
tention shown at day 1 (figure 2). Moreover, recent data
suggest that omapatrilat treatment is superior to capto-
pril in improving the altered endothelial function of a
model of salt-sensitive hypertension [12,13]. It is also in-
teresting to add that some authors have shown that
SHRs, or at least some substrains of SHR, can be identi-
fied as salt-sensitive [14], in a similar way as other clas-
sical salt-sensitive rat models such as the DOCA-salt or
the Dahl-sensitive rats. However, the animals used in the
present study did not show this tendency to increase
their blood pressure in response to salt loading.
Thus, it can be concluded that chronic treatment with
omapatrilat decreases blood pressure in SHRs, resetting
the pressure natriuresis relationship to a normal level,
thus without altering the normal salt-independence of
this arterial hypertension model.
Material and Methods
Male spontaneously hypertensive rats (SHR) and their
normotensive controls (WKY), born and raised in the
Animal House of the Universidad de Murcia, were used
for the study (16 weeks of age). The animals were main-
tained on standard rat chow and tap water throughout
the study, unless otherwise stated. All experiments were
performed according to the guidelines of the European
Union for the ethical treatment of the animals.
Experimental groups and protocol
Four groups of 8 animals each were used in the present
study. One group of WKY and SHR rats served as the un-
treated controls and one more group of WKY and SHR
were treated chronically for 15 days with omapatrilat (40
mg/kg/day in the drinking water).
To construct the renal function curves, the animals were
housed in metabolic cages and after 2 days of getting
used to the cages, sodium balance (mEq/day) was calcu-
lated daily by subtracting sodium intake [food intake (g/
day) ×  0.104 mEq/g (sodium content of the food)] and
sodium excretion [diuresis (ml/day) ×  urine sodium con-
centration (mEq/l)]. Two periods of four days each were
observed. In the first one (normal sodium intake), the
animals were offered normal pulverized rat chow and tap
water. In the second one (high sodium intake), started
immediately after the normal sodium period, sodium in-
take was elevated 8 times by adding the appropriate
amounts of NaCl to the rat chow. Blood pressure was
measured twice in each period, before the period started
and after the period finished. In the case of the groups
treated with omapatrilat, the animals were housed in the
metabolic cages only the last 8 days of the treatment, to
obtain the normal salt and the salt loading responses.
Blood pressure was determined by the tail cuff method
(Cibertec, Madrid, Spain) by using MacLab software (AD
Instruments, UK) in a Macintosh LCII computer. This
approach allowed the estimation of systolic and diastolic
blood pressures, and then of mean arterial pressure.
Urine samples were measured by gravimetry, centri-
fuged and frozen to measure urinary creatinine and sodi-
um concentrations. A small blood sample was also
obtained from the tail at the moment of blood pressure
measurement for measurement of plasma creatinine.
Analytical techniques
Glomerular filtration rate was estimated as the clearance
of creatinine (urine to plasma concentration ratio times
diuresis). Plasma and urine creatinine were measured by
the Jaffe reaction using a commercially available kit
(Boehringer Manheim, Barcelona, Spain). Sodium con-
centration was measured by an ion selective electrode.
Statistical Methods
Data are presented as means ± S.E.M. A repeated meas-
ures analysis of variance was used to obtain the statisti-
cal significance between and within groups. DifferencesBMC Pharmacology 2001, 1:5 http://www.biomedcentral.com/1471-2210/1/5
were considered statistically significant at a P level lower
than 0.05.
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